Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Dec;42(13):1964-70.
doi: 10.1007/s00259-015-3155-x. Epub 2015 Aug 9.

The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis

Seong-Jang Kim  1 , Kyoungjune Pak  2 , Phillip J Koo  3 , Jennifer J Kwak  3 , Samuel Chang  4
Affiliations
Meta-Analysis

The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis

Seong-Jang Kim et al. Eur J Nucl Med Mol Imaging. 2015 Dec.

Abstract

Purpose: This study was performed to evaluate the efficacy of (177)Lu-labelled peptide receptor radionuclide therapy (PRRT) in patients with inoperable or metastatic neuroendocrine tumours (NETs).

Methods: Systematic searches of MEDLINE and EMBASE databases were performed using the keywords of "neuroendocrine", "(177)Lu" and "prognosis". All published studies of neuroendocrine tumours treated with (177)Lu-labelled radiopharmaceuticals and evaluated with either Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 or Southwest Oncology Group (SWOG) criteria or both were included. If there was more than one published study from the same institution, only one report with the information most relevant to this study was included. Each response criteria group was analysed for disease response rates and disease control rates, defined as the percentages of patients with complete response (CR) + partial response (PR), and CR + PR + stable disease (SD), respectively, to a therapeutic intervention in clinical trials of anticancer agents. The pooled proportions are presented with both a fixed-effects model and random-effects model.

Results: Six studies with 473 patients (4 in RECIST criteria group with 356 patients, 3 in SWOG criteria group with 375 patients and 1 in both groups) were included. The RECIST criteria group demonstrated disease response rates ranging between 17.6 and 43.8% with a pooled effect of 29% [95% confidence interval (CI) 24-34%]. Disease control rates ranged from 71.8 to 100%. The random-effects model showed an average disease control rate of 81% (95% CI 71-91%). The SWOG criteria group demonstrated disease response rates ranging between 7.0 and 36.5% with a pooled effect of 23% (95% CI 11-38%). Disease control rates ranged from 73.9 to 89.1%. The random-effects model showed an average disease control rate of 82% (95% CI 71-91%).

Conclusion: (177)Lu-labelled PRRT is an effective treatment option for patients with inoperable or metastatic NETs.

Keywords: Lutetium; Neuroendocrine tumour; Peptide receptor therapy; Radionuclide therapy.

PubMed Disclaimer

References

    1. J Nucl Med. 2014 Feb;55(2):183-90 - PubMed
    1. Neuroendocrinology. 2012;95(2):157-76 - PubMed
    1. J Nucl Med. 2013 Oct;54(10):1689-96 - PubMed
    1. J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S - PubMed
    1. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S - PubMed

MeSH terms

LinkOut - more resources